Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice

Wei Wang, Jiang Jiang Qin, Sukesh Voruganti, Ming Hai Wang, Horrick Sharma, Shivaputra Patil, Jianwei Zhou, Hui Wang, Debabrata Mukhopadhyay, John K. Buolamwini, Ruiwen Zhang

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Background & Aims The oncogene MDM2, which encodes an E3 ubiquitin ligase, is overexpressed in pancreatic cancers and is therefore a therapeutic target. Current inhibitors of MDM2 target the interaction between MDM2 and P53; these would have no effect on cancer cells that do not express full-length P53, including many pancreatic cancer cells. We searched for a compound that specifically inhibits MDM2 itself. Methods We performed a virtual screen and structure-based design to identify specific inhibitors of MDM2. We tested the activities of compounds identified on viability, proliferation, and protein levels of HPAC, Panc-1, AsPC-1, and Mia-Paca-2 pancreatic cancer cell lines. We tested whether intraperitoneal injections of one of the compounds identified affected growth of xenograft tumors from Panc-1 cells, or orthotopic tumors from Panc-1 and AsPC-1 cells (injected into pancreata), in nude mice. Results We identified a compound, called SP141, which bound directly to MDM2, promoting its auto-ubiquitination and degradation by the proteasome. The compound reduced levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation, with 50% inhibitory concentrations <0.5 μM (0.38-0.50 μM). Increasing concentrations of SP141 induced increasing levels of apoptosis and G2-M-phase arrest of pancreatic cancer cell lines, whether or not they expressed functional P53. Injection of nude mice with SP141 (40 mg/kg/d) inhibited growth of xenograft tumors (by 75% compared with control mice), and led to regression of orthotopic tumors. Conclusions In a screen for specific inhibitors of MDM2, we identified a compound called SP141 that reduces levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation and ability to form tumors in nude mice. SP141 is a new class of MDM2 inhibitor that promotes MDM2 auto-ubiquitination and degradation. It might be further developed as a therapeutic agent for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)893-902.e2
JournalGastroenterology
Volume147
Issue number4
DOIs
StatePublished - Oct 1 2014

Keywords

  • BCL2
  • Chemotherapy
  • P21
  • P53-Independent

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice'. Together they form a unique fingerprint.

  • Cite this

    Wang, W., Qin, J. J., Voruganti, S., Wang, M. H., Sharma, H., Patil, S., Zhou, J., Wang, H., Mukhopadhyay, D., Buolamwini, J. K., & Zhang, R. (2014). Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology, 147(4), 893-902.e2. https://doi.org/10.1053/j.gastro.2014.07.001